VIR Biotechnology (VIR) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is VIR's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serio…

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serio…

Vir Biotechnology NASDAQ: VIR said its combination treatment for chronic hepatitis delta met the primary and key secondary endpoints in the pivotal Phase III ECLIPSE 1 trial, with 79% of treated patients achieving undete…

Vir Biotechnology remains a Buy after flawless Phase 3 ECLIPSE 1 results and a major new Gilead partnership. VIR's Hepatitis Delta therapy achieved 44% primary endpoint success and 79% undetectable virus rates, with a st…

Vir Biotechnology, Inc. ( VIR ) Discusses ECLIPSE 1 Topline Results and Expanded SOLSTICE Data November 9, 2026 8:30 AM EST Company Participants Kiki Patel - Head of Investor Relations Marianne De Backer - President, CEO…

Vir stock catapulted to a nearly two-year high Monday on a "clean win" for its experimental hepatitis D treatment.…

The mean of analysts' price targets for Vir Biotechnology (VIR) points to a 75.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising…

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced new, expanded data from the Phase 2 SOLSTICE trial evaluating monthly subcutaneous administration of elebsiran and tobevibart in adul…

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced positive topline results from the pivotal Phase 3 ECLIPSE 1 trial evaluating monthly subcutaneous administration of elebsiran and tob…

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the pivotal Phase 3 ECLIPSE 1 trial evaluating the combination of elebsiran and tobevibart for chro…

Vir Biotechnology NASDAQ: VIR expects to report the first phase 3 results for its experimental hepatitis delta treatment in the fourth quarter of 2026, with data from two additional studies due in the first quarter of 20…

Vir Biotechnology, Inc. (VIR) Q3 2026 Earnings Call Transcript…

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.8. This compares to a loss of $1.17 per share a year ago.…

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the third quarter ended September 30, 2026. “We are entering an important period…

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, President and Chief Executive Officer, will present at the Jefferies 2026 London Healthca…

SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced the appointment of Suzanne Topalian, M.D., to its Board of Directors, effective October 27, 2026. Dr. Topalian is the Bloombe…

VIR's PRO-XTEN platform has attracted major pharma collaborations, validating its dual-masked T-cell engager technology for oncology and solid tumors. Near-term catalysts include ECLIPSE program readouts for hepatitis de…

REGENXBIO (NASDAQ: RGNX - Get Free Report) and Vir Biotechnology (NASDAQ: VIR - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on …

Gilead Sciences expands its oncology pipeline through a Vir Biotechnology deal worth up to $1.74 billion in additional milestones, targeting three novel cancer therapies.…

Vir Biotechnology Inc. (NASDAQ:VIR) announced a major collaboration with Gilead Sciences Inc. (NASDAQ:GILD) to create three novel T-cell engagers (TCEs) aimed at treating solid tumors.…

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN® dual-masked T-cell engager (TCE) dev…

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked T-c…

Vir Biotechnology (NASDAQ: VIR - Get Free Report) and uniQure (NASDAQ: QURE - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the stre…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

